Loading
Onvansertib is an oral serine/threonine kinase inhibitor from Cardiff Oncology, in registered phase 2 trials for colorectal cancer.
Onvansertib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Cardiff Oncology, in colorectal cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. Connects to PLK1.
1.Onvansertib slips into a pocket on PLK1.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Onvansertib" OR ABSTRACT:"Onvansertib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Onvansertib, not a curated reading list.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.